Dallons, M.; Alpan, E.; Schepkens, C.; Tagliatti, V.; Colet, J.-M.
Correction: Dallons et al. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells. Cells 2020, 9, 2177. Cells 2025, 14, 1574.
https://doi.org/10.3390/cells14201574
AMA Style
Dallons M, Alpan E, Schepkens C, Tagliatti V, Colet J-M.
Correction: Dallons et al. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells. Cells 2020, 9, 2177. Cells. 2025; 14(20):1574.
https://doi.org/10.3390/cells14201574
Chicago/Turabian Style
Dallons, Matthieu, Esma Alpan, Corentin Schepkens, Vanessa Tagliatti, and Jean-Marie Colet.
2025. "Correction: Dallons et al. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells. Cells 2020, 9, 2177" Cells 14, no. 20: 1574.
https://doi.org/10.3390/cells14201574
APA Style
Dallons, M., Alpan, E., Schepkens, C., Tagliatti, V., & Colet, J.-M.
(2025). Correction: Dallons et al. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells. Cells 2020, 9, 2177. Cells, 14(20), 1574.
https://doi.org/10.3390/cells14201574
